399 related articles for article (PubMed ID: 34064974)
1. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.
Michel M; Kaps L; Maderer A; Galle PR; Moehler M
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064974
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.
Li H; Rokavec M; Jiang L; Horst D; Hermeking H
Gastroenterology; 2017 Aug; 153(2):505-520. PubMed ID: 28435028
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma.
Tomicic MT; Dawood M; Efferth T
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439227
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
6. The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies.
Braumüller H; Mauerer B; Andris J; Berlin C; Wieder T; Kesselring R
Cells; 2022 Dec; 12(1):. PubMed ID: 36611932
[TBL] [Abstract][Full Text] [Related]
7. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
Zeng K; Chen X; Hu X; Liu X; Xu T; Sun H; Pan Y; He B; Wang S
Oncogene; 2018 Oct; 37(41):5534-5551. PubMed ID: 29899406
[TBL] [Abstract][Full Text] [Related]
8. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
9. Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing.
Intarajak T; Udomchaiprasertkul W; Bunyoo C; Yimnoon J; Soonklang K; Wiriyaukaradecha K; Lamlertthon W; Sricharunrat T; Chaiwiriyawong W; Siriphongpreeda B; Sutheeworapong S; Kusonmano K; Kittichotirat W; Thammarongtham C; Jenjaroenpun P; Wongsurawat T; Nookaew I; Auewarakul C; Cheevadhanarak S
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336886
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors.
Sakai E; Fukuyo M; Matsusaka K; Ohata K; Doi N; Takane K; Matsuhashi N; Fukushima J; Nakajima A; Kaneda A
Cancer Sci; 2016 Jun; 107(6):820-7. PubMed ID: 26991699
[TBL] [Abstract][Full Text] [Related]
11. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.
Fonseca AS; Ramão A; Bürger MC; de Souza JES; Zanette DL; de Molfetta GA; de Araújo LF; de Barros E Lima Bueno R; Aguiar GM; Plaça JR; Alves CP; Dos Santos ARD; Vidal DO; Silva GEB; Panepucci RA; Peria FM; Feres O; da Rocha JJR; Zago MA; Silva WA
BMC Cancer; 2021 Mar; 21(1):207. PubMed ID: 33648461
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in colorectal cancer.
Armaghany T; Wilson JD; Chu Q; Mills G
Gastrointest Cancer Res; 2012 Jan; 5(1):19-27. PubMed ID: 22574233
[TBL] [Abstract][Full Text] [Related]
13. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hasbullah HH; Musa M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769370
[TBL] [Abstract][Full Text] [Related]
15. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
17. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
18. Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe.
Asl ER; Rostamzadeh D; Duijf PHG; Mafi S; Mansoori B; Barati S; Cho WC; Mansoori B
Life Sci; 2023 Feb; 315():121361. PubMed ID: 36608871
[TBL] [Abstract][Full Text] [Related]
19. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
20. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas.
Gocke CD; Benko FA; Kopreski MS; McGarrity TJ
Ann N Y Acad Sci; 2000 Apr; 906():44-50. PubMed ID: 10818595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
